Fleming AD, Mellor J, Jiang W, Storkey A, Styles CJ, McKeigue PM, Colhoun HM. Safe and efficient 2-year screening intervals allocated by manual and automated grading in nationwide diabetic retinopathy screening. Poster presented at the 58th EASD Annual Meeting; September 19, 2022. Stockholm, Sweden. [abstract] Diabetologia. 2022 Aug 3; 65(supplement 1):372. doi: 10.1007/s00125-022-05755-w
Mellor J, Jiang W, Fleming AD, Styles CJ, Storkey A, McKeigue PM, Colhoun HM, Scottish Diabetes Research Network. Evaluation of deep learning prediction models for cardiovascular risk prediction using fundus images from the Scottish Diabetic Retinopathy Screening programme. Poster presented at the 58th EASD Annual Meeting of the European Association for the Study of Diabetes; September 19, 2022. Stockholm, Sweden. [abstract] Diabetologia. 2022 Aug 3; 65(Supple 1):S408-9. doi: 10.1007/s00125-022-05755-w
Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019 Aug;44(4):495-507. doi: 10.1111/jcpt.12830
Sawant RV, Goyal RK, Rajan SS, Essien EJ, Patel HK, Sansgiry SS. Factors associated with intention to engage in self-protective behavior: the case of over-the-counter acetaminophen products. Res Social Adm Pharm. 2016 Mar;12(2):327-35. doi: 10.1016/j.sapharm.2015.06.005
Goyal RK, Rajan SS, Essien EJ, Sansgiry SS. Effectiveness of FDA's new over-the-counter acetaminophen label warning requirements in improving consumer risk perception of liver damage. J Clin Pharm Ther. 2012 Dec;37(6):681-5. doi: 10.1111/j.1365-2710.2012.01371.x.
Evans MF, Poulos C, Smith VK. Who counts in evaluating the effects of air pollution policies on households? Non-market valuation in the presence of dependencies. J Environ Econ Manage. 2011 Jul 1;62(1):65-79.
Nagar S, Mehta S, Bhatara V, Aparasu R. Health care consequences of black-box warnings for antidepressants in the United States and Canada. Res Social Adm Pharm. 2010 Mar;6(1):78-84.
Berria R, Rosenstock J, Silberman C, Davis KL, Horton ES. Weight loss and associated changes in glycaemic control and cardiovascular biomarkers in patients with type 2 diabetes mellitus receiving incretin therapies in a large cohort database. Poster presented at the 44th General Assembly of the European Association for the Study of Diabetes; September 2009. [abstract] Diabetologia. 2009 Sep; 52(Suppl. 1, Abst.755):S297.
Smith VK, Mansfield CA. Buying time: real and hypothetical offers. J Environ Econ Manage. 1998;36(3):209-24.